LOGIC Version 1.0

  • Research type

    Research Study

  • Full title

    Study of Sulphonylurea Synergy with Incretins (LOGIC)

  • IRAS ID

    240142

  • Contact name

    Ewan R Pearson

  • Contact email

    e.z.pearson@dundee.ac.uk

  • Sponsor organisation

    University of Dundee

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Insulin is the chemical signal that controls your blood sugar level. Type 2 diabetes is an illness where the body doesn’t make enough insulin, or insulin doesn’t work properly, causing high blood sugar levels. When the stomach receives food, the digestive system sends out signals known as the “incretin effect”. This effect is reduced in type 2 diabetes. Glucagon Like Peptide 1 or “GLP-1” is one hormone of this effect. GLP-1 signals to the pancreas to “Prepare for Action” and prepare to make insulin, so that when your blood sugar rises following a meal, your pancreas is ready to secrete insulin. Therefore, increasing GLP-1 can help in management of type 2 diabetes.

    Our research team are investigating how one of the common medicines for diabetes, gliclazide, works alongside the incretin effect. We are investigating why some people respond better to than otgers. We think that using gliclazide at a much lower dose than is normally used, could help to “prime” the pancreas and work with GLP-1 to enhance insulin production. If true, diabetes treatments could be used more effectively.

    For this study, we are looking for participants with type two diabetes who are treated with diet alone, or with a tablet called metformin.

    The study will last approximately 8 weeks, during which participants will have five visits to the Clinical Research Centre at Ninewells Hospital in Dundee.

    The first visit will be an initial visit to ensure they understand the information pack, answer any questions, check initial bloods to ensure they are safe to participate, and sign a consent form. The further four visits will be for special infusion tests which will examine how gliclazide and incretins affect our body.

    All potential participants who express interest will be given an information pack which contains further study details.

  • REC name

    East of Scotland Research Ethics Service REC 1

  • REC reference

    18/ES/0064

  • Date of REC Opinion

    4 Jun 2018

  • REC opinion

    Further Information Favourable Opinion